SORL1 and Alzheimer disease: While the secondary downstream effects induced by SORL1 depletion in the endo-lysosomal system are interesting and likely relevant to AD’s ultimate pathogenesis, from a therapeutic perspective it is best to target SORL1’s primary defect, which seems to localize to the endosomal recycling pathway.